氯吡格雷在抗血小板治疗中的临床应用

被引:5
作者
鲁胜
机构
[1] 蚌埠市第三人民医院东南大学医学院附属蚌埠第三医院药剂科
关键词
氯吡格雷; 血小板聚集抑制剂; 动脉粥样硬化缺血性疾病; 抗血小板治疗;
D O I
暂无
中图分类号
R543 [血管疾病];
学科分类号
1002 ; 100201 ;
摘要
血小板在动脉粥样斑块形成和斑块破裂后血栓形成中起关键作用。氯吡格雷为新一代的血小板聚集抑制剂,是目前在动脉粥样硬化缺血性疾病预防治疗中广泛研究的抗血小板药物。现就氯吡格雷在抗血小板治疗中的临床应用予以综述。
引用
收藏
页码:2505 / 2508
页数:4
相关论文
共 17 条
[1]   氯吡格雷对非ST抬高急性冠脉综合征病人炎症因子及其预后的影响 [J].
陈玉国 ;
孙祎 ;
张运 ;
徐峰 ;
吕瑞娟 ;
李瑞建 .
中国新药与临床杂志, 2006, (06) :413-416
[2]   负荷剂量的氯吡格雷在38例急性心肌梗死直接支架术中的应用 [J].
罗心平 ;
施海明 ;
倪唤春 ;
朱军 ;
王彩萍 ;
李剑 ;
范维琥 .
中国新药与临床杂志, 2004, (10) :667-670
[3]  
新编药物学[M]. 人民卫生出版社 , 陈新谦等主编, 2003
[4]  
2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina[J] . Theodore D. Fraker,Stephan D. Fihn.Journal of the American College of Cardiology . 2007 (23)
[5]   Premorbid antiplatelet use and ischemic stroke outcomes [J].
Sanossian, N ;
Saver, JL ;
Rajajee, V ;
Selco, SL ;
Kim, D ;
Razinia, T ;
Ovbiagele, B .
NEUROLOGY, 2006, 66 (03) :319-323
[6]  
Dual Antiplatelet Therapy With Clopidogrel and Aspirin in Symptomatic Carotid Stenosis Evaluated Using Doppler Embolic Signal Detection: The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) Trial[J] . Hugh S. Markus,Dirk W. Droste,Manfred Kaps,Vincent Larrue,Kennedy R. Lees,Mario Siebler,E Bernd Ringelstein.Circulation . 2005 (17)
[7]  
Immunogenetic Susceptibility of Atherosclerotic Stroke: Implications on Current and Future Treatment of Vascular Inflammation[J] . Thomas J. DeGraba.Stroke . 2004 (11 S)
[8]  
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial[J] . Hans-Christoph Diener,Julien Bogousslavsky,Lawrence M Brass,Claudio Cimminiello,Laszlo Csiba,Markku Kaste,Didier Leys,Jordi Matias-Guiu,Hans-Jürgen Rupprecht.The Lancet . 2004 (9431)
[9]  
Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial[J] . Deepak L. Bhatt,Eric J. Topol.American Heart Journal . 2004 (2)
[10]  
The Warfarin and Antiplatelet Therapy in Heart Failure Trial (WATCH): rationale, design, and baseline patient characteristics[J] . Barry M. Massie,William F. Krol,Susan E. Ammon,Paul W. Armstrong,John G. Cleland,Joseph F. Collins,Michael Ezekowitz,Syed M. Jafri,Christopher M. O’Connor,Milton Packer,Kevin A. Schulman,Koon Teo,Stuart Warren.Journal of Cardiac Failure . 2004 (2)